From what 5 stock analysts predict, the share price for United Therapeutics Corp (UTHR) might increase by 54.75% in the next year. This is based on a 12-month average estimation for UTHR. Price targets go from $309.00 to $375.00. The majority of stock analysts believe UTHR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedUTHR 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect United Therapeutics Corp to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on UTHR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
chris shibutani Goldman Sachs | Sell | $213.0 | maintained | Oct 24, 2023 |
greg harrison Bank of America Securities | Sell | $177.0 | reiterated | Sep 29, 2023 |
geoff meacham Bank of America Securities | Sell | $150.0 | reiterated | Feb 22, 2023 |
ravi mehrotra Evercore ISI | Sell | $120.0 | downgraded | Dec 11, 2014 |
In 2023, UTHR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that UTHR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
SPLK-USD
$154.42
TEAM-USD
$216.17
$42.33
TXN-USD
$162.4
TXG-USD
$49.11
TWKS-USD
$4.41